Purchase Order 75N93023P00773

This purchase order contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. for $28,510.03. Under the terms of the contract, IDT will provide custom synthesis, purification, normalization, and delivery of nine antisense oligonucleotides to the National Institute on Drug Abuse by August 15, 2023. The ASOs will support neurotoxicity studies evaluating a potential platform for predicting adverse effects of...

This is a firm fixed-price Blanket Purchase Agreement (BPA) call awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Bio-Synthesis, Inc. (doing business as Dnaexam) for the custom synthesis of oligonucleotides. The contract has a ceiling value of $29,580.00 and an ultimate completion date of February 28, 2010. The agency indicates a high demand and usage level for these oligonucleotides, particularly for a recombinant vaccine project against...

Genscript USA Incorporated will provide gene synthesis services to the National Institutes of Health's National Institute of Allergy and Infectious Diseases under a $12,500 firm fixed price purchase order. The one-year contract was awarded on September 14, 2023 and runs through September 13, 2024. Genscript will deliver the gene synthesis work from its location in Piscataway, New Jersey. No subcontractors or additional context were provided regarding the specific research being supported under...

The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 1,536 antisense oligonucleotides targeting the CHCHD10 gene. The $102,915.50 contract has an August 29, 2022 completion date and does not have a set-aside designation. IDT is a manufacturer of nucleic acid products that has previously supported...

This non-competitive contract award from the National Institutes of Health's National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. is for $20,026.50 to provide custom synthesis of nine antisense oligonucleotides for a neurotoxicology study. Per the solicitation, IDT will synthesize the oligos using proprietary machines and deliver the highest accuracy in sequence. They will also offer design support and expertise. The period of performance is August 7-21,...

The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $248,857.00 Firm Fixed Price purchase order to Genscript USA Inc., a biotechnology company, for the provision of "FAST GENE SYNTHESIS" services. The contract has an August 7, 2023 completion date and was awarded on August 8, 2022. Genscript is a for-profit organization that provides gene synthesis, gene editing, custom protein and antibody production, and other molecular biology services to...

This firm fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. for $701,584. The contract calls for the synthesis of 13,492 antisense oligonucleotides in support of an ongoing SARS-CoV-2 study for the NIH National Institute on Drug Abuse. As the incumbent contractor, Integrated DNA Technologies previously synthesized the oligonucleotides...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a Firm Fixed Price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 9 antisense oligonucleotides (ASOs) in support of a liver toxicity study. The order has a potential value of $24,912.77 and a completion date of August 24, 2023. IDT is a manufacturer of nucleic acid products that has previously provided a range of goods and...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $14,779.98 firm fixed price purchase order to Genscript USA Inc. for transient expression, purification and plasmid preparation services in support of AMBIS program activities. Performance will take place in Piscataway, New Jersey over a two month period concluding on September 30, 2023. The contract calls for Genscript to deliver requested biomanufacturing...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $21,095.60 contract is for the provision of custom gene synthesis services to support NIAID's biomedical research and public health initiatives. Genscript USA Inc. is an experienced federal contractor, having received numerous...